What to do when your Lp(a) is elevated.

What Lp(a) is

Take an LDL particle — the standard atherogenic delivery van — and attach an extra protein called apolipoprotein(a) to it. That is lipoprotein(a). The addition matters because apo(a) closely resembles plasminogen, a protein involved in dissolving clots, but has no fibrinolytic activity of its own. So an Lp(a) particle plausibly does damage through two channels at once: it deposits cholesterol in the artery wall like any other apoB particle, and it may interfere with clot breakdown.⁷ It is also independently linked to calcific aortic valve stenosis, which is not true of ordinary LDL.¹

Why it behaves differently from every other lipid

Your Lp(a) concentration is set overwhelmingly by the LPA gene you inherited. It is not meaningfully changed by diet, exercise, or weight loss, and it does not drift much with age. Statins do not lower it — and may raise it slightly — although statins still reduce risk in people with high Lp(a) by lowering everything else.⁷

This has one genuinely convenient consequence: because the value is stable, current European Atherosclerosis Society guidance is that Lp(a) should be measured at least once in every adult's lifetime.¹ You do not need to keep re-checking it, and you cannot fail at improving it.

One practical wrinkle worth knowing: Lp(a) is reported either as a mass (mg/dL) or a particle concentration (nmol/L), and the two are not reliably interconvertible — the old habit of multiplying mg/dL by 2.5 performs poorly. Modern analyses favour measuring directly in the units you intend to use rather than converting.⁸ If you are comparing an old result to a new one, check the units before concluding anything changed.

Is it really causal?

This is settled about as firmly as observational human biology gets. Two landmark 2009 studies made the case using genetics: a Copenhagen population study showed that people carrying LPA variants that raise Lp(a) had a correspondingly increased risk of myocardial infarction,² and a large genome-wide analysis independently identified LPA variants as strongly associated with both Lp(a) level and coronary disease.³ Because the genetic variant you inherit is assigned essentially at random at conception and cannot be influenced by your lifestyle, this design removes the usual confounding that plagues nutritional epidemiology.

The relationship is continuous — there is no clean threshold at which risk switches on — and it is independent of your LDL cholesterol.⁷

What actually changes when your Lp(a) is high

This is the part that matters, and the part most articles skip in favour of listing drugs that are not yet available. An elevated Lp(a) acts as a piece of information that reclassifies your risk, and once your risk category moves up, several other targets move with it.

1. Your ApoB and LDL targets get tighter

Tightening these is the most important consequence of the result. Lp(a) contributes risk that you cannot currently remove, so the rational response is to remove more of the risk you can. In guideline terms, elevated Lp(a) is a risk-enhancing factor that pushes you into a higher risk category — and each higher category carries a lower apoB and LDL goal.^1,9,10 Someone who might otherwise have been managed with lifestyle and observation may reasonably warrant lipid-lowering therapy; someone already on treatment may warrant a lower target and a second agent to reach it.

The mechanistic logic is straightforward. Total atherogenic particle burden is what drives plaque, and lowering apoB reduces events roughly in proportion to the absolute reduction achieved.¹⁰ If part of your particle burden is fixed by genetics, the modifiable part has to come down further to reach the same total. Our companion article on what to do about a high ApoB covers how that is actually done.

2. Everything else gets treated harder too

Blood pressure, smoking, glucose metabolism, and visceral adiposity all multiply against an already elevated baseline. A person with high Lp(a) has less margin for an untreated blood pressure of 145/90 than someone without it. Smoking cessation moves from important to urgent.¹

3. Imaging becomes more useful

When treatment intensity is genuinely uncertain, looking directly for plaque — with a coronary artery calcium score or carotid ultrasound — often resolves the question faster than another round of risk estimation.⁹ A high Lp(a) with visible plaque and a high Lp(a) with clean arteries at 45 are different clinical situations.

4. Your heart valve goes on the list

Because Lp(a) is independently associated with calcific aortic valve stenosis, periodic attention to the aortic valve — starting with actually listening for a murmur, and echocardiography if one is found or symptoms appear — belongs in long-term follow-up.¹

5. Your family needs testing

Lp(a) is inherited in a straightforward, largely co-dominant fashion, so your first-degree relatives have roughly a coin-flip chance of also being elevated. Cascade testing of family members is one of the highest-yield things a single result can trigger — particularly if there is a history of premature cardiovascular disease in the family.¹

What about drugs that lower Lp(a)?

The honest state of play as of mid-2026 is mixed. Several agents — antisense oligonucleotides and small interfering RNA therapies — lower Lp(a) dramatically. In a phase 2 trial, olpasiran reduced Lp(a) by more than 90% at higher doses,⁵ and a 2026 network meta-analysis of 51 randomised trials confirmed that this class produces far larger Lp(a) reductions than PCSK9 inhibitors, which lower it by only around 20–30%.⁶

What none of them has yet shown is that lowering Lp(a) reduces heart attacks and strokes. Cardiovascular outcome trials are running and have not reported; the authors of that same meta-analysis were explicit that findings should be interpreted cautiously pending those results.⁶ Until an outcome trial reads out positive, "we can lower the number" and "we can lower your risk by lowering the number" remain different claims.

This is worth being clear-eyed about, because it cuts both ways. It means you should be sceptical of anyone selling you an Lp(a)-lowering intervention today. It also means that if you are found to have very high Lp(a) and established disease, asking your physician about clinical trial eligibility is a reasonable conversation to have.

What not to do

• Do not chase the number with supplements. Nothing available over the counter meaningfully lowers Lp(a), and nothing has been shown to reduce events by doing so.
• Do not rely on niacin. Older guidance recommended it because it lowers Lp(a), but subsequent large outcome trials failed to show cardiovascular benefit from adding niacin to statin therapy, and it is no longer a mainstream recommendation.⁷
• Do not conclude that a statin is pointless because it will not touch your Lp(a). The point of the statin is to lower the rest of your apoB burden, which is precisely the strategy an elevated Lp(a) calls for.^4,10
• Do not panic. Around one in five people carry this, most of them never knowing. It is a reason to be systematic, not a diagnosis of impending disaster.

The summary, in one sentence

An elevated Lp(a) does not currently give you a drug to take — it gives you a lower apoB target, a stronger reason to control blood pressure and glucose, a case for looking directly at your arteries, a valve to keep an eye on, and a family worth testing.